Oncolytics Biotech Provides Update on Special Meeting of Shareholders

Oncolytics Biotech has provided an update regarding its upcoming special meeting of shareholders, originally planned for December 15, 2025.7 5

The special meeting has been cancelled and will be rescheduled due to external circumstances arising from a government shutdown.6 8 7

One of the main proposals at the meeting is to approve moving the company's jurisdiction of incorporation from Canada to Nevada, as previously announced in October 2025.2 7 5

Shareholders will also be asked to vote on the adoption of a new incentive award plan as part of the proposals to be considered at the rescheduled special meeting.2

Oncolytics has filed a registration statement and related materials to inform shareholders about the proposals, available in relevant securities regulatory filings and on the company’s website.2 7

Oncolytics Biotech is a clinical-stage biotech firm advancing development of pelareorep, with ongoing efforts in metastatic breast and pancreatic cancer.2 3

The company encourages all shareholders to carefully review the information in the preliminary and definitive management circular/prospectus once it is available.2 7